HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
August 21, 2024 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert...
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
July 31, 2024 07:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial...
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
July 03, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application...
HUTCHMED to Announce 2024 Half-Year Financial Results
June 26, 2024 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six...
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
June 24, 2024 05:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in...
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
June 21, 2024 16:00 ET
|
HUTCHMED (China) Limited
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the...
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
June 16, 2024 20:00 ET
|
HUTCHMED (China) Limited
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of...
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
June 06, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I...
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
June 02, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from FRUTIGA,...
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 23, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from...